Page last updated: 2024-09-03

iguratimod and Glomerulonephritis, Lupus

iguratimod has been researched along with Glomerulonephritis, Lupus in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (16.67)	24.3611
2020's	5 (83.33)	2.80

Authors

Authors	Studies
Fu, J; Liu, Z; Lu, W; Xu, J; Xue, L	1
Bao, C; Dai, M; Du, F; Kang, Y; Li, Q; Liu, B; Yan, Q; Ye, P; Zhang, M	1
Bao, C; Dai, M; Dai, Q; Du, F; Fu, Q; Kang, Y; Lu, L; Wang, R; Wu, C; Yan, Q; Ye, P	1
Dai, X; Fang, X; Jin, L; Li, M; Li, X; Tao, J; Wang, Y; Xia, Y	1
Bao, C; Dai, M; Du, F; Huang, X; Jiang, G; Kang, Y; Li, Z; Tang, J; Wang, N; Wang, X; Xu, J; Xue, Q; Yan, Q; Ye, P; Zhang, X; Zhou, Y	1
Bao, C; Chen, S; Dai, D; Du, F; Fu, Q; Huang, X; Yan, Q	1

Trials

1 trial(s) available for iguratimod and Glomerulonephritis, Lupus

Article	Year
Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study). Trials, 2021, Aug-11, Volume: 22, Issue:1 Topics: Azathioprine; Chromones; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Sulfonamides; Treatment Outcome	2021

Article

Year

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).

Trials, 2021, Aug-11, Volume: 22, Issue:1

Topics: Azathioprine; Chromones; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Sulfonamides; Treatment Outcome

2021

Other Studies

5 other study(ies) available for iguratimod and Glomerulonephritis, Lupus

Article	Year
Iguratimod alleviates tubulo-interstitial injury in mice with lupus. Renal failure, 2022, Volume: 44, Issue:1 Topics: Animals; beta Catenin; Cadherins; Chromones; Epithelial-Mesenchymal Transition; Fibronectins; Fibrosis; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; p38 Mitogen-Activated Protein Kinases; Sulfonamides; Transforming Growth Factor beta1	2022
Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study. Frontiers in immunology, 2023, Volume: 14 Topics: Humans; Immunosuppressive Agents; Lupus Nephritis; Prospective Studies; Treatment Outcome	2023
Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. Arthritis research & therapy, 2020, 03-30, Volume: 22, Issue:1 Topics: Adolescent; Adult; Chromones; Cohort Studies; Drug Resistance; Female; Humans; Immunosuppressive Agents; Induction Chemotherapy; Investigational New Drug Application; Lupus Nephritis; Male; Middle Aged; Remission Induction; Salvage Therapy; Sulfonamides; Treatment Outcome; Young Adult	2020
Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus. International immunopharmacology, 2021, Volume: 96 Topics: Animals; Antibodies, Antinuclear; Arthritis, Rheumatoid; Chromones; Cytokines; Disease Models, Animal; Forkhead Transcription Factors; Humans; Immunoglobulins; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred BALB C; Proteinuria; Sulfonamides; T-Lymphocytes, Regulatory; Terpenes; Th17 Cells	2021
Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PloS one, 2014, Volume: 9, Issue:10 Topics: Animals; Biomarkers; Chromones; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Female; Immunologic Factors; Lupus Nephritis; Lymphocyte Subsets; Mice; Mice, Inbred MRL lpr; Molecular Weight; Sulfonamides	2014